CN117143224B - 一种重组人纤连蛋白截短肽及其制备方法与应用 - Google Patents
一种重组人纤连蛋白截短肽及其制备方法与应用 Download PDFInfo
- Publication number
- CN117143224B CN117143224B CN202311401037.0A CN202311401037A CN117143224B CN 117143224 B CN117143224 B CN 117143224B CN 202311401037 A CN202311401037 A CN 202311401037A CN 117143224 B CN117143224 B CN 117143224B
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- human fibronectin
- truncated peptide
- stem cells
- fibronectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000000130 stem cell Anatomy 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 230000021164 cell adhesion Effects 0.000 claims abstract description 12
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 28
- 210000002379 periodontal ligament Anatomy 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 230000001131 transforming effect Effects 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 abstract description 17
- 102000016359 Fibronectins Human genes 0.000 abstract description 17
- 238000000746 purification Methods 0.000 abstract description 9
- 239000000654 additive Substances 0.000 abstract description 3
- 230000000996 additive effect Effects 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 3
- 102000037865 fusion proteins Human genes 0.000 abstract description 3
- 108020001507 fusion proteins Proteins 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 108020004705 Codon Proteins 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 244000172533 Viola sororia Species 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000005811 Viola adunca Nutrition 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000579120 Coliiformes Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- -1 nanoliposomes Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- WZJVQUUBEVDURL-UHFFFAOYSA-N pentanedial;phosphoric acid Chemical compound OP(O)(O)=O.O=CCCCC=O WZJVQUUBEVDURL-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311401037.0A CN117143224B (zh) | 2023-10-26 | 2023-10-26 | 一种重组人纤连蛋白截短肽及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311401037.0A CN117143224B (zh) | 2023-10-26 | 2023-10-26 | 一种重组人纤连蛋白截短肽及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117143224A CN117143224A (zh) | 2023-12-01 |
CN117143224B true CN117143224B (zh) | 2024-01-30 |
Family
ID=88912317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311401037.0A Active CN117143224B (zh) | 2023-10-26 | 2023-10-26 | 一种重组人纤连蛋白截短肽及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117143224B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117645664A (zh) * | 2024-01-29 | 2024-03-05 | 英特菲尔(成都)生物制品有限责任公司 | 重组人纤连蛋白标准品及其制备方法、鉴定方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
CN111454350A (zh) * | 2020-06-01 | 2020-07-28 | 广东丸美生物技术股份有限公司 | 一种重组纤连蛋白突变体及其应用 |
CN114409763A (zh) * | 2022-03-15 | 2022-04-29 | 湖南华腾制药有限公司 | 一种重组纤连蛋白肽的纯化方法 |
CN115850447A (zh) * | 2022-10-27 | 2023-03-28 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法、核酸 |
CN116333097A (zh) * | 2023-03-28 | 2023-06-27 | 深圳市卫光生物制品股份有限公司 | 一种高活性的重组人纤连蛋白及其制备方法和应用 |
CN116640204A (zh) * | 2023-04-14 | 2023-08-25 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法用途、核酸、表达载体及菌株 |
-
2023
- 2023-10-26 CN CN202311401037.0A patent/CN117143224B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
CN111454350A (zh) * | 2020-06-01 | 2020-07-28 | 广东丸美生物技术股份有限公司 | 一种重组纤连蛋白突变体及其应用 |
CN114409763A (zh) * | 2022-03-15 | 2022-04-29 | 湖南华腾制药有限公司 | 一种重组纤连蛋白肽的纯化方法 |
CN115850447A (zh) * | 2022-10-27 | 2023-03-28 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法、核酸 |
CN116333097A (zh) * | 2023-03-28 | 2023-06-27 | 深圳市卫光生物制品股份有限公司 | 一种高活性的重组人纤连蛋白及其制备方法和应用 |
CN116640204A (zh) * | 2023-04-14 | 2023-08-25 | 深圳柏垠生物科技有限公司 | 耐热纤连蛋白及其制备方法用途、核酸、表达载体及菌株 |
Non-Patent Citations (2)
Title |
---|
Crystal structure of a heparin- and integrin-binding segment of human fibronectin;A Sharma等;《EMBO J》;第18卷(第6期);第1468-1479页 * |
纤连蛋白(FN)国内研究开发及临床应用新进展;王斌等;《基础医学与临床》;第32卷(第08期);第964-967页,特别是第964页左栏第1段-右栏第1段,"2.1" * |
Also Published As
Publication number | Publication date |
---|---|
CN117143224A (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117143224B (zh) | 一种重组人纤连蛋白截短肽及其制备方法与应用 | |
US20220348639A1 (en) | Human collagen 17-type polypeptide, production method therefor and use thereof | |
EP3009502B1 (en) | Cell culture equipment coated with laminin fragments in dry state | |
WO1999005301A1 (fr) | Procede de transfert de genes a l'aide d'un milieu exempt de serum | |
CN106519042A (zh) | 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因 | |
CN110577592B (zh) | 一种重组人纤连蛋白肽 | |
CN111393531A (zh) | 一种亚单位融合蛋白CD2V-Fc及其制备方法和应用 | |
CN101235365A (zh) | 一种高效生产腺病毒的方法 | |
JP7459362B1 (ja) | 組換えヒト型化コラーゲンおよびその応用 | |
CN116333097A (zh) | 一种高活性的重组人纤连蛋白及其制备方法和应用 | |
CN101503468B (zh) | 一种与花粉萌发和/或花粉管生长相关的蛋白及其编码基因与应用 | |
CN111139222A (zh) | 一种重组间充质干细胞及其制备方法和用途 | |
CN113402591A (zh) | 基于棘突蛋白基因修饰干细胞的新型冠状病毒疫苗、其制备方法及应用 | |
CN116063459B (zh) | 一种高表达和高活性纤连蛋白突变体及其应用 | |
CN112358537A (zh) | 一种重组hEGF在毕赤酵母中的生产方法 | |
CN101397573A (zh) | 表达胶质源性神经营养因子的慢病毒载体及其用途 | |
CN115724945B (zh) | 一种纤连蛋白突变体及其应用 | |
CN117003889B (zh) | 一种重组热稳定纤连蛋白及其应用 | |
CN117143223B (zh) | 一种生物合成人体结构性材料的制备方法 | |
WO2024036839A1 (zh) | 一种表达pah的基因修饰细胞药物及其制备方法与应用 | |
CN114958912B (zh) | 一种hek293细胞瞬时表达转染用试剂和瞬时表达系统转染方法 | |
CN114671946B (zh) | 一种重组人iii型胶原蛋白及其制备方法和应用 | |
CN1060811C (zh) | 组建重组腺病毒伴随病毒包装系统的自主复制载体及应用 | |
CN116804061A (zh) | 一种长效抑制人冠状病毒膜融合的高分子及其应用 | |
CN112961232B (zh) | 一种BanLec重组蛋白及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240228 Address after: Room 1203, Building 4 (self numbered D), No. 18 Shenzhou Road, Huangpu District, Guangzhou City, Guangdong Province, 510000 Patentee after: Guangzhou Jike Meichuang Life Science Co.,Ltd. Country or region after: China Address before: 510000 3rd floor, No.37, Huajing Road, Tianhe District, Guangzhou, Guangdong Province Patentee before: Guangzhou Jinan University Medical Biotechnology Research and Development Center Co.,Ltd. Country or region before: China |